TELA Bio vs Xtant Medical
TELA and XTNT side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TELA and XTNT compare
TELA Bio and Xtant Medical are about the same size, with market caps of $42.3M and $37.9M.
TELA Bio grew revenue faster over the last twelve months (1.5% versus −14.3% for Xtant Medical).
Xtant Medical keeps more of each dollar of sales as profit, with a net margin of −10.2% compared with −53.6% at TELA Bio.
Xtant Medical scores higher on the StockData Score (9 against 3 for TELA Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TELA | XTNT |
|---|---|---|
| Size and price | ||
| Market cap | $42.3M | $37.9M |
| Share price | $0.942 | $0.270 |
| Change, 1 year | −20.9% | −64.1% |
| Change, 5 years | −92.5% | −69.7% |
| Beta (5Y) | 0.64 | 0.60 |
| Employees | 218 | 151 |
| StockData Score | ||
| Total score | 3 | 9 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 0 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.5× | 0.3× (better) |
| P/B | – | 0.9× |
| FCF yield | −81.3% | −1.8% (better) |
| Fair value | – | $1.08 |
| Margin of safety | – | 74.9% |
| Growth | ||
| Revenue growth (TTM) | 1.5% (better) | −14.3% |
| Revenue growth, 5Y average | 34.5% (better) | 20.2% |
| Profitability | ||
| Gross margin | 67.2% (better) | 59.4% |
| Operating margin | −43.2% | −9.6% (better) |
| Net margin | −53.6% | −10.2% (better) |
| FCF margin | −44.0% | −0.64% (better) |
| Return on equity | – | −25.2% |
| Return on invested capital | −238% | −15.8% (better) |
| Financial health | ||
| Debt / equity | – | 0.28 |
| Interest coverage | −4.3× | −3.8× (better) |
| Current ratio | 0.61 | 2.16 (better) |
| Altman Z-score | −13.19 | −2.65 (better) |
| Piotroski F-score | 3 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 70.5% | 106% |
| Held by insiders | 41.0% | – |
| Insider net buying, 12 months | $186K | – |
| Short interest, % of float | 2.2% | – |
Go deeper
- TELA stock overview
- TELA income statement
- TELA valuation and score
- XTNT stock overview
- XTNT income statement
- XTNT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.